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This report is a summary of the research conducted in the
Sleep Research and Treatment Center supported in part by NASA
Grant NGR-009-204. This research was carried out netween 1 June
1971 and 28 February 1975. The general goals of this grant were
three-fold: (1) A continuing evaluation was made of toe effects
of various hypnotics on various sleep stage parameters and on the
parameters of effe • tiveness. (2) A continuing evaluation was
also made of the effects of several commonly usA yet distinctly
different hypnotics on performance. (3) At the request of NASA,
the effects on performance of two non-hypnotics commonly used in
the space program were also evaluated.
Until the last decade there has been little exacting and
objective research into the fundamental biological process of
sleep even though approximately one-third of our lives are spent
In this state. Our sleep laboratory alo g with others have now
begun to make inroads into this complex subject. Recent research
has alieady provided significant contributions to the diagnosis
and treatment of sleep disorders and mental disorders and to a
better understanding of the aging process as well as to the effects
of drug action on the central nervous system. Sleep laboratory
studies have also evaluated the relationship between a night's
sleep and daytime performance, e.g., the effects of varying
amounts of sleep loss. An area that has not been thoroughly
studied is the effects on daytime performance of commonly used
hypnotics taken the previous night.
i
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I. EFFECTS OF HYPNOTICS ON SLEEP STAGE AND EFFECTIVENESS PARAMETERS
Past Studies
Effects of Short-Term Hypnotic Use on Sleep Stages
In our past studies, we have utilized a standard eight-night
protocol to determine if hypnotic drugs altered sleep patterns. The
first placebo night allows for adaptation to the laboratory, while
the second and third placebo nights are used for baseline measure-
ments. On the next three nights, the active drug is administered
at "lights out" and the initial and short-term cumulative effects
of the drug on sleep patterns can be measured. On the last two
nights, placebo is again administered and withdrawal effects, if
any, are observed.
A number of our short-term studies based on this eight-night
protocol have shown that many drugs produce significant alterations
in REM sleep. The following drugs, in the doses listed, produce a
decrease in REM sleep and were followed by a rebound of REM sleep
(increase above baseline levels) on withdrawal: glutethimide
(Doriden) 500 mg; secobarbital sodium (Seconal) 1CO mg; pentobarbital
sodium (Nembutal) 100 mg; wethyprylon (Noludar) 300 mg, methaqualone
(Quaalude) 300 mg; and diphenhydramine (Benadryl) 50(; Ong, Ov the other
hand, the following drugs produced eitheT ro deorea:ie or minimal changes
in RE,1 sleep in the doses given, nor were they (with one exception)
followed by REM rebound on withdrawal: chloral hydrate 500 mg and
1000 mg; chlordiazepoxide (Librium) 50 mg; diazepam (Valium) 10 mg;
and promethazine (Phenergan) 25 mg. However, following withdrawal
of promethazine there was a marked increase in REM sleep on withdrawal.
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Further, we have evaluated several benzodiazepine drugs, e.g.,
flurazepam (Dalmane) 30 mg; triazolam (U33030) 5 mg and flunitrazepam
(RO54200) 1 and 2 mg each of which produced decreases in REM sleep
during initial administration. Upon withdrawal REM sleep returned
to normal values without a rebound of REM sleep. Finally, there
are a few drugs which produce an immediate increase in REM sleep
during administration. These include thioridazine (Mellaril) 50,
75 and 100 mg and ORF 8063 (20 mg), an investigational benzodiazepine
drug.
Because we scored all stages of sleep (often not previously
done), our studies also demonstrated that in addition to producing
changes in REM sleep, a number of drugs produce decreases in stage 4
sleep. These included three hypnotics: flurazepam 30 mg; glutethimide
50 mg and diazepam 10 mg. The most marked decreases in stage 4 sleep
occurred following the administration of the benzodiazepine drugs,
flurazepam and diazepam. The decrease in stage 4 sleep occurred on
the first night of pentobarbital administration, while the decrease
in stage 4 sleep with the other four drugs did not occur until the
second or Lhird consecutive drug nights.
Evaluation of Hypnotic Drug Effectiveness
A particular fccus of hypnotic evaluation has been the degree
and length of t he effectiveness of these drugs in inducing and
maintaining sleep in insomniac patients. The experimental protocol
for these studies is described as fol.l-)ws: The first placebo night
allows for adaptation to the laboratory environment and then on nights
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2-4 baseline measurements are obtained. On nights 5-7, initial
and short-term effectiveness in inducing and maintaining sleep
is measured. Nights 17-18 mark the end of the two-week period
of drug administration and these laboratory nights allow for
determining if the drug is still effective or if tolerance has
developed.
We have evaluated individually the following drugs and dosages
with this 22 night protocol.: chloral hydrate 1000 mg; ethclorvynol
(Placidyl) 500 mg; glutethimide 500 mg; methaqualone (Sopor) 150 and
300 mg; methaqualone HCL (Parest) 400 mg; secobarbital 100 mg;
flu razepam 30 mg and triazolam 0.5 mg.
We found that all of the drubs were intially moderately to mark-
edly effective in inducing or maintaining sleep, or both	 owever,
we found that at the end of the two-week period of drug administration,
a loss of effectiveness had developed for either sleep induction or
maintenance or both, with all of these drugs except flurazepam 30 mg.
Effectiveness of Hypnotic Drugs Used Chronically
The most striking finding in a study previously described of
chronic hypnotic drug users was the poor sleep experienced by these
insomniac patients in spite of their continued hypnotic use. The
results showed that all of these patients had as great or greater
difficulty, either in falling asleep, staying asleep or both, when
compared to age-matched insomniac control subjects who were not
taking drugs. Seven of the ten patients taking medication had
values for total wake time which were either similar to or greater
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than the insomniac controls. At least one of the three key
parameters for measuring hypnotic drug effectiveness - sleep
latency, wake time after sleep onset, or total wake time - was
evaluated in every patient over the insomniac controls.
We consider the continued effectiveness and safety of a
hypnotic drug to be the primary factor in recommending its use.
However, there have been very few studies in which the effectiveness
of a hypnotic drug has been evaluated beyond several consecutive
nights to one week of drug administration let alone for periods
of months. The major implication of our sleep laboratory studies
evaluating hypnotic drug effectiveness relates to the need for
clearly establishing the effectiveness of a hypnotic drug with
continued use.
Drug Withdrawal Insomnia
We have described a condition which we refer to as Drug Withdrawal
Insomnia, which results from both psychological factors and physio-
logical changes involved in drug withdrawal. When a patient abruptly
withdraws from the regular and prolonged use of multiple doses of a
hypnotic, he frequently first experiences marked insomnia, i.e.,
difficulty in falling asleep. This insomnia is due to psychological
apprehension over his ability to get along without the drug and
also an abstinence syndrome which includes jitteriness and nervous-
ness. In addition, once the patient falls asleep, 'iis sleep is
frequently fragmented and disrupted.
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If the hypnotic which is abruptly withdrawn is a REIN suppressant
ind there is a marked increase or rebound in REM sleep there may
also be associated an increased intensity and frequency of dreaming.
At times even nightmares may occur. It should be emphasized that
altered sleep patterns and Drug Withdrawal Insomnia can occur riot
only when a drug is intentionally withdrawn but also on an actual
drug night when the patient slept past the duration of pharmacologic
action of the drug.
Current Studies
Effects of Long-Term Hypnotic Use
Withinthis current grant period, we have evaluated flurazepam
30 mg and pentobarbital 100 mg when adminis,cred for a one month
period. The protocol was as follows: 1-4 placebo-laboratory;
5-7 drug-laborator y-; 8-15 drug-home; 16-18 drug-laboratory; 19-29
drug-home; 30-32 drug-laboratory; 33-36 placebo-laboratory; 37-44
placebo-home and 45-47 placebo-laboratory. The results of this
study are briefly summarized in Table 1A and 1B. Within the table
are the mean values for 4 effectiveness parameters (sleep latency,
N•ake time after sleep onset, total wake time and number of wakes).
These are followed by two sleep stage parameters, % slow wave sleep
(stage 3 and 4 sleep) and % REM sleep. The P values represent the
k	 pv.•obability levels obtained when contrasting a specified condition
1	 tIEdn with the baseline via a Dunnett multiple comparison test.
11 1
The results seen with pentobarbital administration are similar
to what have been seen previously. This drug is initially effective,
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i.e. total wake time is significantly decreased from 62.2 min.
on baseline to 41.5 min. on short-term drug. This effectiveness
is not, however, maintained. By the end of two weeks the total
wake time has returned to baseline levels and remains there.
Flurazepam administration, showed similar initial effectiveness.
The total wake time decreased from 67.1 on baseline to 34.5 on short-
term drug (P < .01). At the end of two weeks and three weeks admin-
istration, the total wake '.Lme of this drug was still significantly
(P < .01) decreased (29.4 & 1 8.5 min. respectively).
The two drugs showed a different picture in terms of sleep stages
also. They both produced a decrease in 7 REM sleep. Pentobarbital
decreased the % REM from 22.5 to 21.7, 20.8, & 21.5 during shoic,
intermeelate, and long-term drug administration. There was a sugges-
tion of a rebound following initial withdrawal (24.4). With flurazepam
administration a similar but significant decrease in % REM was seen
(26.2 vs. 22.9, 19.4, & 22.2). Upon withdrawal trire was no evidence
of rebound (26.2 vs. 25.5, & 25.2).
With slow wave sleep, pentobarbital initially produced a decrease
from 7.9 to 5.0. The % slow wave returned to baseline by the end of
two weeks of drug administration. By the end of four weeks, the
slow wave had exceeded baseline values (7.9 vs. 9.5) and continued to
rise upon initial drug withdrawal (10.2). Flurazepam administration
decreased slow wave sleep significantly (P t .01) across all conditions
(16.4 vs. 9.2, 7.2, & 5.6). These sleep stages partially returned with
f^	 initial withdrawal (6.0%) and were similar to baseline after two weeks
.I
-8-
of withdrawal (13.0X).
This study supported what we had previously reported both in
terms of sleep stages and in terms of effectiveness. Both drugs were
initially effective. At the end of two weeks administration, only
flurazepam was still effective and its effectiveness was mantained
throughout the one month of drug administration. Both drugs de-
creased REM and slow wave sleep. Flurazepam did this signLficantl.y
across all conditions. With pentobarbital there was a nonsignificant
increase in REM sleep on withdrawal which was not seen with flurazepam.
V
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1I. PERFORMANCE FOLLOWING ADMINISTRATION OF 11Y?NOTICS
The s , !con.i area of ins • , tigation in this gran.. concerns the
effects of administrating various commonly prescribed hypnotics
upon subsequent daytime performance. Most performance studies
have been criticized (e.g. Chiles) as being extremely difficult
to relate to the "real world." He Fuggests that this is due to
the fact that few experimental tasks exist which can approximate
the complexity of the real world. One reason for this is due to
the desire of most researchers to simp;ify the tasks so that they
can be measured and quantified easily. Alternatively, most exper-
imental tasks are prevented from their goal of being realistically
complex because not enough time is available or allowed due to
pressures at the moment. Further, the facilities necessary to con-
duct this type of research are rarely available, due to prohibitive
costs. Thus, part of what we are reporting here is the evolvement
of our Performance Evaluation Laboratory towards the more complex
types of tasks alluded to by Chiles above. Specifically, our measure-
ments evolved over a period of time from very simple observational
techniques to the more objective paper and pencil evaluation of mood
and performance. As we progressed to more active non paper and pencil
evalu<.tions, we more rigidly controlled our measurement task by isolating
our subjects to eliminate the interaction among our subjects and other
external contaminants. Then we began the inclusion of more complex
tasks which ultimately included the subject's time-sharing of multiple
tasks. This step has brought us closer to the real world in terms of
the realistic complexities within our tasks, while at the same time
10-
keeping our measurements and analysis task at least managable.
Past Work
In order to place what we have done during; this contract in a
better perspective, we will first b iefly summarize our previous
work that was supported in part by prior NASA grants and contracts.
1. In one study, 4 subjects were involved in an evaluation
of chlordiazepoxide 50 mg, chloral hydrate 1000 rag; and
secobarbital 100 mg counter-balanced with placebo. The
tasks employed were Wilkinson's Addition, Digit Symbol
Substitution Test, Pursuit Rotor and Flow Maze. The
,uhjects were evaluated over a four hour period following;
four hours of sleep.
2. A nine night protocol (PPPPDDPPP) was employed to evaluate
3 different drugs (secobarbital 100 mg, glutethimide 500
mg and flurazepam 30 mg;). Three subjects were tested in
three separate 9 night protocols (counter-balanced for
drug condition) with the Wilkinsor Addition, Digit Symbol
Substitution Test, Moscowitz Vigilance and Divided Atten-
tion and the Pursuit Rotor.
3. The same subjects were again evaluated using the same drugs
in a three night protocol (P D P). This time they were eval-
uated 90 minutes following administration.
4. Two insomniac subjects were studied over a 22-night protocol
in which there were 4 placebo baseline nights, 14 drug nights
(secobarbital 100 mg) and 4 placebo withdrawal nights. The
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task used was a card sorting one described by Crossman
which was done immediately upon arising, in the A.M.
The data that was compiled in these studies was summarized by
looking at the time course of the various drugs in terms of how
much intervening sleep was allowed. These conclusions though
speculative were helpful in designing further research.
Glutethimide was eliminated from this summary as the effects
of this drug were riot sufficiently consistent.
Performance 90 Minutes After Drug Administration Without Intervening Sleep .
All of the tests which resulted in consistent trends suggested that
at the approximate peak action of flurazepam and secobarbital there was
a decrement when compared to placebo. This decrement was somewhat
greater on secobarbital. These tests included cognitive-association
type (Wilkinson Conti;.iuous Addition Task and Digit Symbol Substitution
Test) and motor coordination (Pursuit Rotor).
Performance Four Hours After Drug Administration With Intervening Sleep
The drugs studied were secobarbital, chloral hydrate and chlordi-
azepoxide. In this instance the cognitive-association type tests
(Wilkinson Continuous Addition Task and Digit Symbol Substitution
Test) showed a decrement, again somewhat greater with secobarbital.
On the other hand, the motor coordination tasks (Pursuit Rotor and
Flow Maze) showed an enchancement over placebo on all drug conditions.
(These results may be partially confounded with sleep deprivation and
with previous drug administration).
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Performance 8 Hours After Drug Administration With Intervening Sleep
In the cognitive-association type tasks, there appeared to ht,
general decrement with both flurazepam and secobarbital. With seco-
barbital the decrement was significant. In the motor-type tasks there
was a significant decrement with secobarbital. The card sorting task
(decision process) suggested that a decrement occurred with both seco-
barbital and flurazepam, and this decrement was greater with secobar-
bital. With long-term administration of secobarbital, both the effective-
ness of the drug and the decrement in performance decreased considerably.
Current Work
udy One
Two major studies were carried out in this section. In the first
study, eight male and eight female subjects were used. These 16 sub-
jects were studied acr-ss a 4-week period. They slept in the laboratory
the same 2 consecutive nights each week in four groups of four subjects
each. The first night in the laboratory was considered an adaptation
night and the subjects all received placebo. The second night in the
laboratory the subjects received one of the 4 drug conditions specified.
These were flurazepam 30 mg, secobarbital 100 mg, phenobarbital 100 mg
and placebo. The subjects were assigned to one of these four groups in
terms of their daily schedule. Within the groups the assignment to the
specific protocol was according to a randomized Lain square. This
counter--balancing was done in such a way that each drug was present in
each group for every testing session.
Two complete practice sessions were made at the subjects' con-
venience prior to testing sessions. During the testing sessions, the
.r
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subjects were toted twice each week. The :'_-st time was in the
evening prior to the administration of the drug. Thus, this session
was also considered practice. The second testing session was the
following morning. This testing session was preceded by drug admin-
istration and 8 hours of sleep.
The testing session itself involved all four subjects simultaneously.
They each were seated around a 3' X 8' table which was partitioned into
4 equal 1.5' X 4' areas. The partition was 2' tall and was built of
accousticil material such that communication among the 4 subjects was
maintained at a minimum.
The testing schedu a every morning was as follows:
0700 Awaken and dress
0720 .Juice and roll and fill post sleep questionnaire
GM Begin test session
0845 End test session
The test schedule for the evening was similar except that no juice or
roll was supplied and no questionnaire was filled out.
The performance tasks that were used in this study are as follows:
1. Simple Reaction Time - This task employed the traditional pradigm
in that a warning tone preceded the visual stimulus which was a
single flash of a photostimulator by approximately 5 seconds.
50 stimuli were presented to obtain a valid representative of the
0
	 response speed. A single variable was obtained from this task
(mean response latency).
2. Critical Flicker Frequency - This task along with the next one
were included as they have been shown to detect drug differences
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and are reportedly measuring arousal or cortical excitability.
The stimulus was prsesented via a Grass Photostimulater (PS-2).
Three consecutive fusions for all subjects were used as the
criteria to finish a trial. Four trials for each session were
collected using the traditional method of constant stimuli.
The mean frequency of fusion w.zs the only variable obtained.
3. Auditory Flutter Frequency - This task has been reported by
previous authors to be more sensitive to drug effects than
the critical flicker frequency. Tt,e method of collection was
the paired comparison technique. This method forced a decision
between a 100 cycle flutter and a variable frequency flutter
between 10 and 100 cycles in steps of 10. The variable derived
from this task was the mean fusion frequency.
4. Wilkinson Vigilance Task with Reactive Time - This task con-
sists of a tone which occurs once every 2 seconds for a 1 hour
period. Periodically one of these tones is slightly shorter
than the rest. The shorter tones are the stimulus and the
subject is requested to identify them by pushing on a hand held
push button. The tones are masked in white noise such that
a well trained observer will perceive about 80% of the stimuli.
Test and training tapes were obtained from RT Wilkinson of
Cambridge, England. Several variables were obtained from this
task including the number of correct responses, the number of
incorrect responses, the number of attempted responses, the
mean latency between stimulus onset and response onset, d'
(this is a detection therapy estimate of discriminability be-
tween signal and noise) and an estimate of habituation. This
b
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latter estimate was derived from the number correct within
the first fifteen minutes minus the number correct within
the last fifteen minutes.
5. Paced Matti - This task consisted of a prerecorded verbal
presentation of two numbers followed by a pause. During the
pause the subject's task was to add the two digits and record
the answer. Preliminary work showed that the pace employed
in most sleep loss studies (1.5 . 2 sec) was inadequate for our
subjects. We chose a pace of 0.25 sec per stimulus presentation,
i.e., the first stimulus was followed by the second in 0.25
sec which was followed by a 0.25 sec pause before the next two
stimulus were presented. Possibly, the major difference between
our subjects and previously published results is that our sub-
jects were of high or ,above overage intelligence, i.e., medical
students, graduate students and their wives. Three variables
were derived from this task. The number of correct additions,
the number of additions attempted and a measure of efficiency
derived from the percent correct.
6. Pursuit Rotor -- This task consisted of a turntable with a
diameter spot near the outer edge. The turntable was rotating
at a speed of 60 RPM. The subject held a stylus in his preferred
hand and attempted to keep this stylus in contact with the rotating
spot. The variable derived from this task was the mean time on
target derived from three 30 second trials.
The post sleep questionnaire was included as a non-performance
measure to yield a subjective estimate of the previous nights sleep.
The specific questions that were asked were:
i
-16-
1. How long do you think it took you to fall asleep last
night?
hours__ min.
2. flow much sleep do you think you got last night?
hours	 min.
3. Did you wake up during the night? l.f yes, how many times 	 _?
The statistical analysis of these data were carried out at two levels.
First, a three way analysis of variance within each variable was made
(sex, subject and condition with the sex and condition parameters fixed).
This analysis tested specifically whether there were any systematic
differences between the male and female samples that could be detected.
Whenever a significant (P <, .05) interaction between sex and condition
was detected any further analysis was made with the male and female
sample rather than the total sample.
The analysis of the total sample that was used to detect differences
due to drug conditions employed the Dunnett comparison test. The error
term for this analysis was the subject by condition interaction term
derived from the analysis of variances described above. If, on the
other hand, a significant sex difference was detected in the three way
analysis of variance then the subject by condition error term for the
Dunnett was derived from the male and female samples separately. The
results of the performance tasks of this first study are described in
Table 2. Within this table, the mean response of each of the various
tasks is given for the males, females and for the total sample. In
general, there was demonstrated a difference due to sex across all
variables. These differences were significant within the simple
reaction time, vigilance d', and vigilance correct, positive slope
An
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variables. Thus, the analysis within these three var'ables was carried
out within the male and female samples rather than the total samples.
Table 2 also describes the conditions that were significantly different
from placebo in terms of probability. Whenever possible the total
sample was employed.
The simple reaction time task waes not analyzed for the total
sample since a sex difference was detected. In other words, the male
sample was significantly faster than the female sample (246.5 msecvs.
304.9 msec). Within the male sample all three drug conditions (253.0,
252.0 & 251.2 cosec) showed a significant decrement when contrasted
with placebo (229.9 msec). This drug effect was not seen within
the female sample (309.6, 249.9 & 300.0 msec. vs. 311.5 cosec).
There were slight decrements suggested when contrasting, flurazepam
administration with placebo in the critical flicker frequency task
(48.6 FPS vs. 49.6 FPS). With phenobarbital administration, there
was a decrement suggested with the critical flicker frequency (48.4
FPS vs. 49.6 FPS). The auditory flutter frequency task suggested a
slight increase due to both secobarbital (72.9 FPS) administration
and phenobarbital (71.0) administration when contrasted to placebo (70.6).
There were several variables derived from the vigilance task. In
general, these results were rather complimentary with themselves and
with the other tasks. First, the number of correct positives was
slightly decreased with f'_urazepam administration (18.3), significantly
decreased with phenobarbital (17.2) and slightly increased with seco-
i
barbital (20.8) when contrasted with placebo (19.3). There was no
^:
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change detected in the number of false positives during flurazepam
administration (4.0), and an increase related to both of the bar-
biturate administrations (5.6 & 4-6) --aien contrasted with placebo
(4.0). The number attempted showed a decrease from 23.2 on placebo
to 22.3 on flurazepam vnd 21.8 on phenobarhita?_. During secobarbital
administration, a significant trend in terms of an increase in the
number attempted was detected (23.2 vs. 26.3). There was also a
tendency to take longer to react within the vigilance task across
all conditions (728.4 cosec vs. 739.0, 740.2 & 765.2 msec). The
estimate of d' from the vigilance data was analyzed separately
for the two sexes. In general, for both sexes there was a tendency
to increase d' on flurazepam and to decrease d' on the barbiturates
except for phenobarbital with the male sample. Finally, the slope
of the correct positives detected a significant difference within
the male sample for both of the barbiturates (-3.8,0.4 vs. 2.5) and
no change with flurazepam administration (2.5 vs. 2.5).
The paced math task was evaluated in terms of three variables.
There was a tendency for fewer correct responses to be made across
the three drug conditions (48.4, 47.8, 46.6 vs. 50.4). There was
r,
also; a tendency for fewer responses to be attempted across all
conditions (54.5, 56.4, 53.4 vs. 57.5). Finally within the paced
math task, there was a significant decrement in terms of efficiency
(percent correct) with secobarbital administration ( 83.5% vs. 86.9%).
The final performance task to be evaluated within this study was
the pursuit rotor in terms of time on target. There was a tendency
for both flurazepam and phenobarbital administration to enhance this
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task while secobarbital administration suggested a slight decrement.
We were able with these subjects to get a subjective estimate of each
subjects sleep during the 8-hour sleep period the night previous to
the performance testing. Table 3 summarizes the subjective, estimate
of sleep latency, total sleep time, and the number of wakes for each
condition. Within each condition a mean is given for the male and
female sample and for the total sample. These data were analyzed
In a manner identical to the performance data. In other words,
these data were first evaluated for differences due to sex. There
were no differences obtained, tit s, .,e remaining analyses were all
done on the total sample. Table 3 also summarizes these results in
terms of probability that the mean drug condition is different from
the placebo baseline.
All three drug conditions demonstrated a decrease in sleep
latency (24.4 min. vs. 18.8, 15.0 & 21.5 min.) for placebo vs.
flurazepam, secobarbital and phenobarbital. All three drugs also
produced anincrease in total sleep time (7.0 hours vs. 7.5, 7.3,
and 7.2 hours). Flurazepam showed a significant increase (P<.05).
All three drugs also produced a decrease in the number of awakenings
reported (2,9 vs. 2.7, 2.7, 2.8). None, however, were significantly
different.
The pattern of changes detected within this study strongly
suggest that there are drug effects on daytime performance following
a single administration of a commonly used hypnotic. It is also
apparent that each of these drugs produce a different pattern of
effects on the performance tasks employed here.
t
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The simple reaction time task measures the general respon-
siveness of an individual in terms of speed. An increase in
reaction time may not nec.ssarily be related only to a decrease in
arousal but as we will discuss later may be related to an increase
in arousal. Within this study, the male sample was significantly
faster than the female regardless of the condition. This firing
is in agreement with previous reports. There was also a difference
between the male and female sample of how they reacted to the effects
of the different drug administrations. Within the male sample but
not the female sample, all three drug conditions caused a significant
decrement in reaction time.
The critical flicker frequency and auditory flutter frequency
have been used to measure cortical excitability or general arousal
level. An increase in the fusion frequency indicates an increase in
the general arousal. Previous studies evaluating the acute effects of
hypnotic drugs demonstrated that detectable changes can be found with
auditory flutter frequency for up to 10 hours following hypnotic drug
administration. The critical flicker frequency, on the other hand,
has shown changes with these same hypnotics for up to 8 hours following
administration. It is important to establish the effects that a drug
may be having on general arousal, as this will affect performance in a
differential manner. It has been documented that a possible waning
effect of the barbiturates is a phase of excitment. 7 Further it has been
demonstrated that as the arousal of a subject increases or decreases
beyond an optimal point, performance will begin to deteriorate. These
two tasks suggest that there may he an increased arousal present with
secobarbital and perhaps a decreased arousal with flurazepam.
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Within the vigilance task following flurazspam administration,
there was a tendency to respond less with a resulting decrease in the
number of correct responses. On the other hand, d' was increased.
What this suggests is that the signal was easier to detect from
noise but the subject was just responding less. Secobarbital
administration, in conCrast, produced a tendency to respond more,
make more false responses along with correct responses and have a
de,..eased d'. In other words, the subjects were responding more
.nd finding it more difficult to detect a signal. Further, contrary
to all previous literature there was little or no habituation or
fatigue detected within the one dour task following barbiturate
administration. These data strongly suggest the hypotheses that
there is a decrease in arousal following flurazepam administration
which is affecting performance. With Secobarbital and less so pheno-
barbital we note an increase in arousal which also results in perfor-
mance decrements.
Finally, in the one task that required sustained concentration
(paced math) the Secobarbital administration produced the only sig-
nificant decrement. Again, this supports the hypothesis that by
increasing the arousal past the optimal point, the performance
efficiency will deteriorate.
In making a decision between the three drugs evaluated in this
study, one needs only to look at the number of significant changes
that were detected. The analysis summary in terms of number of
significant changes supports the further hypothesis that the two
barbiturates are more severe in there detectable performance decrements.
a
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This hypothesis curies more impact when one considers that the
subjects estimated that flurazepam was more effective in enhancing
total sleep time.
Study Two
In this second study, the effects of two commonly used hypnotics
on performance was evaluated by employing tasks which have a high face
validity and an increased complexity. The hypnotics evaluated were
flurazepam, 30 mg and secobarbital, 100 mg. Nine male subjects aged
21-31 years of age with a mean of 24.5 years were tested individually
on the same day each week. Each subject was assigned randomly to one
of 3 different counter-balanced orders. The subjects were above
average in intelligence as all were either medical or graduate students.
All of the subjects abstained from the use of any drugs including mari-
juana and alcohol for the duration of the study.
All performance evaluation was carried out within an accoustically,
ligut and temperature controlled chamber (Industrial Accoustics Co. #402).
The subjects were seated in a comfortable reclining chair which was
facing a screen on which the various stimuli were projected tachisto&-
copically from a two-channel projecting tachistiscope (Ralph Gerbrands
#G1170). Auditory stimuli and instructions were transmitted between
the experimenter and the subject through headsets. This allowed the
subjects to be completely isolated from all external or uncontrolled
stimuli. All tasks were presented in a completely automated manner
via magnetic tape so that each subject was presented exactly the
same material in the same order.
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Prior to the actual testing period, each subject was thorcaghly
trained. In each of three complete practice sessions, subjects were
allowed to take as much time and to ask as many questions as were
necessary to understand the task involved. This training method
enabled subjects to become skilled enough in these tasks so that
the effects due to learning could be minimized.
Each subject arrived at the sleep laboratory at 10:15 P.M. At
11:00 P.M. the subject was in bed and administered either drug or
matching placebo. Lights out was immediately following drug admin-
istration. The next morning at 7:00 A.M. the subject was arov..sed
and allowed to dress and fill out the post sleep questionnaire.
Breakfast followed which consisted of hospital cafeteria fond without
any stimulants. Session I began at 8:00 A.M. and finished by 10:00.
From 10:00 to 10:15 A.M., a rest period was scheduled. At 10:45,
Session II bega ►i and ended at 12:15 P.M. Following the end of
Session II, a one hour break for lunch (all stimulants excluded)
was taken within the hospital cafeteria. Session III and Session
IV were repeated in a similar manner with a fifteen minute rest
period between the two sessions. Thus, Session III began at 1:15
and Session IV was completed at 5:30 P.M..
Each testing day consisted of four 2 hour sessions with ever;
subject following the same routine within a session. The wobble
board task began each session. The subject then entered the chamber
and was presented the remaining tasks. Following the completion of
these tasks the subject was again tested on the wobble board. I
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The taikx employed in this study were as follows:
1. W(bble board - This test estimates gross stability or
cerebellar coordination similar to the Romberg test.
Each subject stood on a slightly raised platform.
This platform was capable of torsionally tilting
approximately 2 degrees in any direction. Any
movement of this platform was detected and in this
way, the number of postural changes were tabulated.
The subject's task was to stand in a relaxed manner
with hi eyes open for 30 seconds, visually fixating
on .. spot on the wall directl. • 'n front of him. The
su'.)ject was then instructed to close his eyes and again
remain motionless for 30 seconds. This whole procedure
was then repeated for a total of six 30 second samples
alternating between the conditions of eyes open and
Eyes closed. This task resulted in 4 variables which
were the number of counts for each of the four conditions.
2. Wilkinson Vigilance - This task and variables were described
within the previous study.
3. Shooting Gallery - This test evaluates performance ability
where target identification and accuracy are required.
The task was patterned after a "penny arcade shooting gallery."
In the first phase the subject, following a brief warning tone,
responded to a 100 msec flash of light on the screen directly
in front of him f aiming and firing 7 hand held light-gun
as quickly and accurately as possible at a small target.
d
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The • arget was a cnlwir ►m sulphide photo cell, one inch in
diameter. In this frist phase of this task, fifty stimuli
were presented approximately ten seconds apart. The length
of time in milliseconds between the onset of the stimulus
and the firing of the gun was recorded along with the
number of times the target was hit.
In the second phase of this task, the subject responded
to a set of visual stimuli presented in the same manner as
in the first phase. The visual stimuli were chosen from all
possible combinations of four colors (red, green, yellow and
blue) and four shapes (triangle, circle, square, and diamond).
Four of thRse color-shape combinations were identified during
the training sessions as being correct and requiring a response.
All possible combinations were presented in each session. Each
of the correct responses (red circle, yellow square, green
triangle, and blue diamond) were presented twelve Cites for a
total of forty eight. The remain!n g twelve possible combinations
were presented once each for a total of twelve presentations.
Thus, the "no response" rate for any given session was 20%. The
response, in this second phase, was again to aim and fire at the
target as quickly and accurately as possible. However, this
time a decision had to be made whether to shoot or not and if
the shot was made, which target of four possible targets was
the correct one. The targets were the same as in th first phase
except that they were located in the four corners of the screen.
In this phase, the latency to shooting response was again
26-
recorded. The number of correct responses (shoot vs. no
shoot) was tabulated along with the number of correct hits.
In both phases, a hit was counted if at least a corner of
the photo cell target was hit by the light spot projected
from the gun. This task resulted in eight variables, the
reaction time, number attempted and number hits for the
simple and choice phase. The choice phase had further the
number of correct and false positives.
4. Baddely Reasoning Test - This task samples "higher mental"
functioning and has previously been shown to be sensitive
to certain drug effects. This test also employed visual
stimuli projected onto the screen following a brief warning
tone. A series of statements followed by a pair of letters
were projected onto the screen, one at a time. 1?xamples of
these stimuli are: "A follows B - AB", "B is not followed by
A - BA." The subjects task was to push the response key if
the statement was correct in relation to the pair of letters
that followed. Thus, this task resulted in two variables,
the number of correct and false positives.
5. Auditory Flutter Fusion - This task was described within the
previous study.
6. Digit. Symbol Substitution Test - This test measures short-
term memory and consisted of a series of digits that were
arbitrarily .assigned to a series of symbols. The subject
was allowed 30 seconds to :study the digit-sym1,v1 relationships.
His task was to substitute the appropriate -,wbo). for each
number represented during the next three minutes. The digit-
i-27-
symbol relationships were changed with earl. subsequent
presentation of the test. This task had two variables,
the number attempted and the number correct.
7. Post Sleep Questionnaire - This questionnaire was des-
cribed within the previous study.
The analysis of these data was based upon a single score for each
day for each subject. These daily subject scores were then analyzed
with the Dunnett multiple comparison t-test contrasting the two hypnotic
conditions with placebo. The results of this study are described within
Table 4. This table presents the mean of each of the three conditions
within each of the task variables. Within this same table are the
results of tho Dminet analysis in terms of probability values for the
contrasts made between each drug condition and placebo.
it can be seen from close inspection of this table that the data
analyzed in terms of an overall daily mean do not show any consistent
changes in relation to the control on placebo condition. There is only
one significant trend. The number correct in the digit-symbol sunsti-
tution test is decreased (P<.1) during flurazepam administration (135.6
vs. 123.1). This is supported by a slight suppression of the auditory
flutter frequency (56.4 vs. 52.8), d' of the vigilance task (2.1627
vs.2.0207) and the reaction scores seen within the shooting gallery
(simple - 510.6 vs. 571.1 ms & choice - 1552.5 vs. 1607.4 ms). None
of these values were statistically significant. They are however
consistent with the first study.
The analysis of the subjective estimate of each nights sleep
derived from the post sleep questionnaire is described in Table 5.
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Both flurazepam and secobarbital produced a decrease in the estimate
of sleep latency over placebo (58.9 min. vs. 37.7 & 30.5 min. respec-
tively). Both drugs also increased the total sleep time 16. 	 .,urs
vs. 7.1 & 7.0 hours) and decreased the number of wakes (2.4 vs. 0.6
& 1.0). The number of wakes was significa. t-ly decreased with both
drugs while a significant trend was seen with flurazepam in terms
of total sleep time and with secobarbital in sleep latency.
It would appear that the changes seen within the performance
tasks in the first study were nu 	 *song enough to effect an overall
day long score. There was, however, a trend suggesting an overall
decrement with flurazepam. If these data were reanalyzed to include
the 2 hour sessions as a parameter it may be possible to ascertain
whether some of the hypothesized effects seen within the first study
were seen within this study. For example, it is possible that changes
of an oscillating nature following barbiturate administration are present.
While we noted an aroused or excited state after awakening in the morning,
we did not note any differences in the average daily response. Thus, i.t
is possible that the original excited state led to one type of error and
a subsequent hypoaroused st '_e to an opposite error, the two cancelling
out each other. At this point we can not rule out the possibility that
something such as this is going on.
It is also possible that the effects seen in the first study may
have been washed out by the increased time between arousal and testing
and/or the inclusion of a meal wtihin this second study. In previously
reported studies, for example, some of the reported effects which were
due to hypnotic drug administration could be changed or eliminated with
the simple administration of a stimulant such as coffee. Obviously,
fA
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if this is the degree of the decrement, then probably under most con-
ditions there is little to be concerned about. On the other hand, when
one considers a manned space flight where split second decisions are
extremely important and lives and countless of millions of dollars are
at stake, then the effects of hypnotic drugs on performance are critical.
In conclusion, we have noted changes in performance that are due
to the administration of a single dose of a hypnotic. These changes
appear to be strongest, upon awakening in the morning. In addition,
these decremental effects appear to be stronger, at least in the morning,
with the barbiturates than with flurazepam. These effects also appear
to be detectable on occasion throughout the entire day following drug
administration. The question remains regarding how strong these effects
really are, e.g., can they be effectively eliminated with a single cup
of coffee? In other words, there still remains the question of whether
we are at times failing to detect changes in performance because there
are no changes there or because our measuring devices are relatively
insensitive to real world complexities.
`	 1	 I	 1
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III. Non-Hypnotic Perfor.nance Evaluation
Study One
At the request of NASA we evaluated two different kinds
of non-hypnotic compounds. The first was to evaluate the amount of
barbiturate potentiation that might be expected from the administration
of Lomotil. 11his drug is used routinely on NASA manned space flights
to slow down the formation of feces during space flight.
We employed the critical flicker frequency to evaluate this drug
in combination with secobarbital. We u3ed four male subjects aged
22-27 who slept in our laboratory for four consecutive nights fc 8
hours each night. The first night was for adaptation purposes so no
evaluation was done. The first two nights, the subjects received
matching placebo at h.s. The third and fourth nights the subjects
received the active drug which was secobarbital 100 mg plus Lomotil
2.5 mg at h.s. The morning following nights 2,3 and 4, each subjects'
critical flicker frequency was established approximately one half hour
after arousal.
There was a decrease in fusion frequency from 56.1 on baseline to
55.0 and 54.1 during drug administration, days 1 and 2 respectively.
The difference between the fusion frequency obtained on the second day
of drug administration and baseline was significant (P <.05).
The morning evaluation of arousal was further supported by the
subjects' reports of side effects of drowsiness throughout the day.
r.
These subjective symptoms of drowsiness did not decrease on the second
day of administration, rather they increased.
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These data suggest that th- use of Lomotil in conjunction with
secobarbital can be decremental to performance. As wv would have
expected, rather strong changes in several performance measures
occurred in conjunction with the decreased arousal. This hypothesis
is clear even though we did not include a control group. Our data
reported in Study One with secobarbital alone, sugge ,:ted an increase
in arousal with subjectG tested at approximately the same time
following arousal from sleep. Further, in two previously published
studies where secobarbital was administered for several consecutive
days, the effects detected by a card sorting task and the Wilkinson.
Vigilance task decreased across the several days of administration.
Thus, the results of this study support the hypothesis that a barb-
iturate related decrement can be potentiated with the simultaneous
administration of Lomotil. This could be a potential l y dangerous
combination in someone performing an extremely critical job.
Study Two
At a further request of NASA we set up to evaluate the
effects of two motion sickness compounds upon performance that are
commonly used by NASA astronauts. These were a combination of a)
scopalamine (.35 mg) and dexedrine (5 mg) and b) promethazine (25 mg)
and ephedrine (50 mg). We were able to monitor only three subjects in
a pilot study in preliminary work with the latter combination. However,
the clinical investigation committee of our institution was unable to
allow further work on either of these c-)mpounds because they were not
FDA approved nor was there as IND number available.
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This study represents the furthest evolvement of the Performance
Evaluation Laboratory. Within this study, we completely redesigned
the tasks such that the tasks employed were more complex and were
beginning to yield some measures of face validity. The major differ-
ence between this study and the previous evaluations was that a single
complex task battery was used rather than a set of separate tasks. The
multiple-complex battery was developed within our laboratory along the
lines of that described by Alluisil The task itself requires a greater
level of skill than any we had employed previously, primarily because
it required tim;- sharing of multiple simultaneous tasks. This variable
of time sharing is considered to be one of the most important variables
required to make a task relatable to the complexity of the "real world"
(Chiles).
The subjects were seated within the previously described accous-
tically controlled chamber in a reclining chair. A response panel was
constructed which rested on the arms of their chair and housed Cie
response keys. A movable stimuluus panel was pc , itioned above the
response panel and housed the meters and warning lights. Above the
stimulus panel and on the wall was located a screen on which were
projected stimuli via a projecting tachistoscope.
The response panel consisted of 6 (series 2N) lighted "microswitches".
These panel switches have an exposed surface area of 1" x 3/4". They
were oriented in an 8" arc 2 1/4 " apart. The set of switches to be
used and the conditional set of stimuli to be monitored were identified
by whether or not a switch was lit and by its color. The stimulus panel
consisted of a panel 12" x lA". On this panel were located a pair of
warning lights which shifted from yellow to red and a pair of meters
(3" x 1 112") which were continually oscillating.
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The multiple-complex battery was developed from a set of tasks
which were as follows:
(1) The Wilkinson Vigilance - this task has been previously
described.
(2) Probability Monitoring - The two meters on the response
panel were driven such that they were continually oscillating
with a mean of zero. Periodically, this mean would shift
slightly. The subjects' task was to respond to this mean
shift as quickly as possible by pressing the appropriate
I	 response key. If the subject responded within 10 seconds,
a response latency in milliseconds was recorded. If the
subject responded within 3 miruteF, a correct response was
recorded and if the subject did not respond within 3 minutes
I	
an error was recorded. When the subject: responded or the
3 minute interval was surpassed, the meter reset itself again
to a mean of zero. The two meters were activated independently
and in a quasi-random manner.
(3) Simple Reaction Time - This task has been previously described.
(4) Target Identification - The stimuli presented in the shooting
gallery task (previously described) were projected on the
screen with a projecting tachistoscope. The subjects' task
was to respond as quickly as possible tothe correct key.
There. were 4 possible responses and one inhibited response -
each of which were equally likely. The number correct and
incorrect were recorded along with the reaction time in terms
of milliseconds.
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(5) Warning Lights Monitoring - This task consisted of two pairs
of lights which periodically shifted from yellow to red. The
subjects' task was to respond as quickly as possible by
pressing the appropriate key on the response panel. As with
the probability monitoring task the time to respond was recorded
in milliseconds if the subject responded in less than 10 seconds.
If he responded in less than 3 minutes a positive response was
recorded. A negative or missed response waQ recorded if the
subject did not respond within 3 minutes. If the subject
responded or the 3 minute interval was up without a response,
the 'Light was reset to its original setting. The two warning
lights functioned independent of each other and of the probability
monitoring task.
(6) Wobble Board - This task has been previously described.
The three subjects were all male between the ages of 22 and 25.
They were trained with three complete training sessions as had been
previously employed. The subjects remained in the hospital or lab-
oratory for the duration of the 5 day study. A drug or matching placebo
was administered each day at 8 A.M. and 8 P.M. On days 1 and 2, the
subjects received placebo and on days 3 through 5 the subjects were
administered the promethiazine and ephedrine compound. Three 2-hour
testing sessions were employed each day at 8:30, 1:30 and 5:30. Each
subject was assigned to one of these sessions. Thus, we confounded
subjects with testing sessions.
The subject began the multiple complex battery when the fourth
response key from the left turned red. This signaled to the subject
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that the auditory vigilance task was to be monitored by itself. At
the end of the first half hour, the switch light in this task along
with the two keys to the right of it were lit green. This change
signaled the subject that the auditory task was to be monitored along
with the probability and warning light monitoring. At the end of the
second half hour, the auditory task ceased and the subject had to
monitor only the probability and warning light tasks. At the end of
the third half hour, the fourth key from the left was again lit (red)
by itself. This was followed by a warning tone and a series of 50
simple reaction times to a 10 msec flash. The first 4 switches from
the left then came on (yellow) and following the next warning tone,
the choice stimuli were presented on the screen and the subject
completed 64 choice stimuli responding with the appropriate key.
This completed the multiple complex battery task. The subject was
removed from the chamber and a wobble board assessment was obtained.
The results of this study are described in Table 6. '['his table has
a mean value for the baseline and for each of the 3 days of drug
administration. It also has the probability level that a specific
drug condition was different from the baseline based upon the
Dunnett multiple comparison test.
The strongest effects were obtained within the vigilance task.
Tn this task a decrease was detected in the number of correct positives
across the three days of drug administration (9.3. 8.9 and 10.3)
which contrasted with baseline (11.7). The number of false positives
i
was significantly decreased (7.7, 5.6, 2.3 vs. 16.0). The d' level
increased slightly on day 1 and 2 (1.8815 and 1.8977 vs. 1.7197) and
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significantly (P< 0.1) on day 3 (2.3745). The number attempted on
this task was likewise significantly decreased across the 3 days
(17.0, 14.7 and 12.7 vs. 27.7 at a probability of .1, .05 and .05).
The reaction time decreased initially on day 1 (858.9 vs.809.5) and
then increased on day 2 (883.1) and day 3 (962.1).
Within the probability monitoring task thert , was a non signif-
icant increase in the percentage detected in the > 10 sec < 3 min
category across all 3 days (15.3 vs.26.9, 23.6 and 27.2). The warn-
ing light monitoring task demonstrated a similar increase (9.4 vs.
23.3). The target identification phase also showed this same initial
decrement. in other words, day 1 reaction Lime was 714.1 vs. 648.3
for baseline and the number correct for day 1 was 43.3 as compared to
47.3.
Within the total multiple complex task, there was a decrement
detected within the three subjects following administration of the
motion sickness compound. The results are consistent with the expected
generalized effects. In other words, the reported complaint of the
astronauts and the ex pected side effects of these drugs would have
predicted a carry over in terms of drowsiness during the day. That
this decrement appears to increase with continued drug administration
clearly in the case of the vigilance task and perhaps also with the
monitoring type tasks, should be taken with great alarm. The fact
remains that in order to show statistical significance with only 3
subjects, the effect must be large and consistent. Thus, a great
deal more work needs to be done to evaluate the safety of this and
the other motion sickness preparation. Finally, this study clearly
p
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demonstrates that our Performance Evaluation laboratory has attained
the sensitivity and utility to answer certain practical questions.
V-38-
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Table lA
Long Term Hypnoti: Administration
Pentobarbital 100 mg
f	 Source BSI.N STD ITD LTD W1 W2
Sleep latency 29.4 22.3 29.9 27.1 28.6 31.0
WTASO 32.8 19.2 .t 31.3 21.9 32.1 32.3
Total Wake Time 62.2 41.5 t 61.2 55.6 60.7 63.3
Number Wakes 24.2 17.4 0 18.2 0 17.50 22.2 25.8
REM 22.5 21.7 20.8 21.5 24.4 22.7
Slow Wave 7.9 5.0 7.5 9.5 10.2 9.8
Table 1B
Flurazepam 30 mg
Source
	 BSLN	 STD	 ITD	 LTD	 W1	 W2
Sleep Latency 38.8 23.6 16.8 24.7 34.9 39.5
WTASO 28.3 10.9° 12.5* 13.8* 24.9 13.0
Total Wake Time 67.1 34.5t 29.4 t 38.5t 60.0 52.5
Number Wakes 14.8 8.80 10.3 12.2 16.7 15.7
7 REM 26.2 22.90 19.4 22.21 25.5 25.2
% Slow Wave 16.4 9. 2 t 7.2 t 5.6 t 6.0 t 13.0
P< .10 = *
P<.05 =0
P < .01 = t	 pRWEDING PAGE BLANK NOT FILMID
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4Table 4
Hypnotic Drug Mean Performance Measures and Probability Values
SOURCE PLACEBO iTLUR^Ct ZE^ECb$tT^tfifF^L
Wilkinson Vigi lance
d' 2.1627 2.0207 2.1218
Number Attempted 24.0 21.7 24.6
Reaction Time 750.3 737.2 693.7
Shootin_ Gal lery
Simple Reaction Time 510.6 571.1 523.2
Number Attempted 49.8 50.0 49.2
Number Hits 30.4 25.5 27.2
Choice Reaction Time 1552.5 1607.4 1589.7
Number Attempted 47.7 48.0 48.0
Number Hits 20.6 19.4 17.9
Number Correct Positives 47.6 47.6 47.4
Number False Positives 0.1 0.3 0.3
Baddel_U
Number Correct Positives 29.7 29.8 29.5
Number False Positives 1.4 1.4 1.4
Auditory Flutter Frequency 56.4 52.8 54.8
Digit_Symbol. Substitution Test
Number Attempted 135.9 123.5 133.1
Number Correct 135.6 123.1* 132.3
Wobble Board
Pre-Eyes	 Opened 57.0 56.6 59.7
Pre-Eyes Closed 101.2 103.1 100.7
Post-Eyes Open 67.9 65.0 60.0
Post-Eyes Closed 110.1 105.9 96.6
P< .10 = *
P< .05 = o
P< .O1 = t
aTable 5
Subjective Sleep Estimates
PLACEBO	 FLURALEPAM	 SECOBARBITAL
Sleep Latency	 58.9
	
37.7 	 30.5 *
Total Sleep Time	 6.5	 7.2 *	 7.0
Number Wakes	 2.4	 0.6 t	 1.0 0
P< .10 = *
P< .05 =0
P< .01 = t
0
.,t•
Table 6
Mean Performance Measures for Motion Sickness Preparation
SOURCE BSLN DRUG
Day 1 Day 2 Day 3
Vigilance
Number Correct Positive 11.7 9.3 8.9 10.3
Number False Positive 16.0 7.7	 0 5.6	
.i
2.3	
.t
d' 1.7197 1.8875 1.8977 2.3745
Number Attempted 27.7 17.0 * 14.7
	 0 12.7
	 0
Reaction Time 858.9 809.5 883.7 962.1
Probability Monotoring
Reaction Time 3017.5 3806.9 3008.6 3309.4
> 10 sec < 3 min 15.3 26.9 23.6 27.2
Warning Light Monitoring
Reaction Time 1015.0 1710.8 1437.8 1843.0	 k
> 10 sec < 3 min 9.4 23.3 9.2 19.3
Simple Reaction Time 288.7 323.2 288.6 260.8
Target Identification
Reaction Time 648.3 714.1 644.8 648.2
Number Correct 47.3 43.3 44.7 45.3
Wobble Board
Eyes Open 26.8 28.7 19.0 20.11
Eyes Closed 108.4 90.0 59.9 62.7
P< .10 = *
P < .05 = 0
P < .O1 = t
1
